Professional
Added to YB: 2026-05-15
Pitch date: 2026-05-13
DNA [neutral]
Ginkgo Bioworks Holdings, Inc.
Author Info
Pernas Research is a former CIO of a $3.5B fund that now share actionable stock research. Sign up for the newsletter.
Company Info
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States.
Market Cap
$544.8M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.13
P/E
-1.55
EV/Sales
3.84
Sector
Life Sciences Tools and Services
Category
growth
Pernas Research Passes On: Ginkgo Bioworks Holdings, Inc.
DNA (pass): Autonomous lab vision gaining coherence post-Biosecurity spin, OpenAI & gov partnerships signal AI bio-infrastructure interest. Rev declining sharply, heavy cash burn, limited proof of durable demand. ~$373M cash, no debt = 2-3yr runway to find product-market fit. Opportunity large if trend materializes but too speculative at current stage.
Read full article (1 min)